STL Volume 31 Number 2

Review of topical ruxolitinib as a promising JAK inhibitor for mild to moderate hidradenitis suppurativa, including early trial results, safety data, and its role in addressing unmet treatment needs.

Read about current and emerging hyperhidrosis treatments including sofpironium bromide, glycopyrronium wipes, botulinum toxin, targeted alkali thermolysis, microwave therapy, and laser options.

Update on Nemolizumab SC injection (Nemluvio®), Gepotidacin tablets (Blujepa®), and Zoliflodacin for oral suspension (Nuzolvence®).